PortalPublikationenMolecular targeted therapies for breast cancer treatment.

Molecular targeted therapies for breast cancer treatment.

Standard

Molecular targeted therapies for breast cancer treatment. / Schlotter, Claus M; Vogt, Ulf; Allgayer, Heike; Brandt, Burkhard.

in: BREAST CANCER RES, Jahrgang 10, Nr. 4, 4, 2008, S. 211.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schlotter, CM, Vogt, U, Allgayer, H & Brandt, B 2008, 'Molecular targeted therapies for breast cancer treatment.', BREAST CANCER RES, Jg. 10, Nr. 4, 4, S. 211. https://doi.org/10.1186/bcr2112

APA

Schlotter, C. M., Vogt, U., Allgayer, H., & Brandt, B. (2008). Molecular targeted therapies for breast cancer treatment. BREAST CANCER RES, 10(4), 211. [4]. https://doi.org/10.1186/bcr2112

Vancouver

Schlotter CM, Vogt U, Allgayer H, Brandt B. Molecular targeted therapies for breast cancer treatment. BREAST CANCER RES. 2008;10(4):211. 4. https://doi.org/10.1186/bcr2112

Bibtex

@article{6276d6ce336d4659aeaba7594df3182b,
title = "Molecular targeted therapies for breast cancer treatment.",
abstract = "Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.",
author = "Schlotter, {Claus M} and Ulf Vogt and Heike Allgayer and Burkhard Brandt",
year = "2008",
doi = "10.1186/bcr2112",
language = "Deutsch",
volume = "10",
pages = "211",
journal = "BREAST CANCER RES",
issn = "1465-5411",
publisher = "BioMed Central Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - Molecular targeted therapies for breast cancer treatment.

AU - Schlotter, Claus M

AU - Vogt, Ulf

AU - Allgayer, Heike

AU - Brandt, Burkhard

PY - 2008

Y1 - 2008

N2 - Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.

AB - Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.

U2 - 10.1186/bcr2112

DO - 10.1186/bcr2112

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 211

JO - BREAST CANCER RES

JF - BREAST CANCER RES

SN - 1465-5411

IS - 4

M1 - 4

ER -